Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5-6/2018

01-08-2018 | Review

Sentinel node evaluation in prostate cancer

Authors: Ramkishen Narayanan, Timothy G. Wilson

Published in: Clinical & Experimental Metastasis | Issue 5-6/2018

Login to get access

Abstract

Sentinel lymph node (SLN) based pelvic lymph node dissection (PLND) in prostate cancer (PCa) is appealing over the time, cost and morbidity classically attributed to conventional PLND during radical prostatectomy. The initial report of feasibility of the SLN concept in prostate cancer was nearly 20 years ago. However, PLND based on the SLN concept, either SLN biopsy of a single node or targeted SLN dissection of multiple nodes, is still considered investigational in PCa. To better appreciate the challenges, and potential solutions, associated with SLN-based PLND in PCa, this review will discuss the rationale behind PLND in PCa and evaluate current SLN efforts in the most commonly diagnosed malignancy in men in the US.
Literature
1.
Cabanas R (1977) An approach for the treatment of penile carcinoma. Cancer 39:456–466PubMed
2.
Spiess PE et al (2007) Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 177(6):2157–2161PubMed
3.
Morton D et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399CrossRef
4.
Bilchik AJ et al (1998) Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 4(6):351–358PubMed
5.
Nieweg O, Tanis P, Kroon B (2001) The definition of a sentinel node. Ann Surg Oncol 8(6):538–541PubMed
6.
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
7.
Wawroschek F et al (1999) The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. Eur Urol 36:595–600PubMed
8.
Ruijter E et al (1996) Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180:295–299PubMed
9.
Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025
10.
Brocks D et al (2014) Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 8(3):798–806PubMed
11.
Mundbjerg K et al (2017) Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol 18(1):3PubMedPubMedCentral
12.
13.
Cheng L et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1):66–73PubMed
14.
Hofer MD et al (2006) Prognostic factors in lymph node-positive prostate cancer. Urology 67(5):1016–1021PubMed
15.
Boorjian SA et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178(3 Pt 1):864–870; discussion 870-1 PubMed
16.
Hull G et al (2002) Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167:528–534PubMed
17.
Schumacher MC et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54(2):344–352PubMed
18.
Bishoff J et al (2000) Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 45(2):270–274
19.
Meng M, Carroll P (2000) When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 164:1235–1240PubMed
20.
Mclaughlin A et al (1976) Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol 115:89–94PubMed
21.
McDowell G et al (1990) Pelvic lymphadenectomy for staging clinically localized prostate cancer. Urology 35(6):476–482PubMed
22.
Makarov DV et al (2006) Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol 176(2):554–558PubMed
23.
Han M et al (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 28(3):555–565
24.
Abdollah F et al (2013) Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol 24(6):1459–1466PubMed
25.
Godoy G et al (2012) Pelvic lymph node dissection for prostate cancer: frequency and distribution of nodal metastases in a contemporary radical prostatectomy series. J Urol 187(6):2082–2086PubMed
26.
Bernstein AN et al (2017) Contemporary incidence & outcomes of prostate cancer lymph node metastases. J Urol 199:1510–1517
27.
Conrad S et al (2002) Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 167(2 Pt 1):521–525PubMed
28.
Wit EMK et al (2017) Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy. Eur Urol 71(4):596–605PubMed
29.
Briganti A et al (2006) Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50(5):1006–1013PubMed
30.
Winter A et al (2014) Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics. Int J Urol 21(1):58–63PubMed
31.
Briganti A et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265PubMed
32.
Mattei A, Danuser H (2011) Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient. Curr Opin Urol 21(3):211–218PubMed
33.
Hacker A et al (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176(5):2014–2018; discussion 2018-9
34.
Fortuin AS et al (2018) Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10(1):e1471
35.
Maurer T et al (2016) Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443PubMed
36.
Schumacher MC et al (2006) Is pelvic lymph node dissection necessary in patients with a serum PSA < 10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 50(2):272–279PubMed
37.
Cagiannos I et al (2003) A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170(5):1798–1803PubMed
38.
Leyh-Bannurah SR et al (2017) Population-based external validation of the updated 2012 partin tables in contemporary north american prostate cancer patients. Prostate 77(1):105–113PubMed
39.
Briganti A et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487PubMed
40.
Buyyounouski MK et al (2017) Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(3):245–253PubMed
41.
Fuchs W, Böök-Hederström G (1961) Inguinal and pelvic lymphography: a preliminary report. Acta Ragiol 56:340–354
42.
Gil-Vernet JM (1996) Prostate cancer: anatomical and surgical considerations. Br J Urol 78:161–168PubMed
43.
Flocks R, Culp D, Porto R (1959) Lymphatic spread from prostate cancer. J Urol 81(1):194–196PubMed
44.
Briganti A et al (2012) Lymphatic spread of nodal metastasis in high-risk prostate cancer: the ascending pathway from pelvis to the retroperitoneum. Prostate 72:186–192PubMed
45.
Park JM et al (1994) Pathways of nodal metastasis from pelvic tumors: CT demonstration. RadioGraphic 14:1309–1321
46.
Golimbu M et al (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121(5):617–620PubMed
47.
Mattei A et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53(1):118–125PubMed
48.
Joniau S et al (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63(3):450–458PubMed
49.
Raghavaiah NV, Jordan WP Jr (1979) Prostatic lymphography. J Urol 121(2):178–181PubMed
50.
Smith M (1966) The lymphatics of the prostate. Invest Urol 3(5):439–444PubMed
51.
Byar D, Mostofi FK (1972) Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30(1):5–13PubMed
52.
Pierorazio PM et al (2013) Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins Hospital 30-year experience. Prostate 73(15):1673–1680PubMed
53.
Weckermann D et al (2007) Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer. BJU Int 99(5):1036–1040PubMed
54.
Harrison SH et al (1992) Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer. Cancer 69(3):750–754PubMed
55.
Heck MM et al (2014) Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study. Eur Urol 66(2):222–229PubMed
56.
Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMed
57.
Winfield HN et al (1991) Urological laparoscopic surgery. J Urol 146(4):941–948PubMed
58.
Schuessler WW et al (1991) Transperitoneal endosurgical lymphadenectomy in patients with localized prostate cancer. J Urol 145(5):988–991PubMed
59.
Touijer K et al (2007) Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 178(1):120–124PubMed
60.
Rousseau C et al (2014) Laparoscopic sentinel lymph node versus hyperextensive pelvic dissection for staging clinically localized prostate carcinoma: a prospective study of 200 patients. J Nucl Med 55(5):753–758PubMed
61.
Fukuda M et al (2007) Detection of sentinel node micrometastasis by step section and immunohistochemistry in patients with prostate cancer. J Urol 177(4):1313–1317; discussion 1317 PubMed
62.
Heidenreich A, Varga Z, Von R, Knobloch (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167(4):1681–1686PubMed
63.
Ganswindt U et al (2011) Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys 79(5):1364–1372PubMed
64.
65.
Clark T et al (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169(1):145–147; discussion 147–8 PubMed
66.
Messing EM et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781–1788PubMed
67.
Hanks GE et al (1998) Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 40(4):765–768PubMed
68.
Moschini M et al (2016) Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy. Eur Urol 69(1):135–142PubMed
69.
Nini A et al (2015) Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival. Eur Urol 68(5):777–784PubMed
70.
Preisser F et al (2018) Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate 78(6):469–475PubMed
71.
Davies JD et al (2013) Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology 81(2):358–363PubMed
72.
Kluth LA et al (2014) Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? Urol Oncol 32(1):47.e1–47.e8
73.
Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158(5):1891–1894PubMed
74.
DiMarco DS et al (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173(4):1121–1125PubMed
75.
Schroder F et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846: a phase III study. J Urol 172(3):923–927PubMed
76.
Kramer SA et al (1981) Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 125(6):817–819PubMed
77.
Seay TM, ML B, Zincke H (1998) Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 159(2):357–364PubMed
78.
Briganti A et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270PubMed
79.
Daneshmand S et al (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172(6 Pt 1):2252–2255PubMed
80.
Bader P et al (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169(3):849–854PubMed
81.
82.
Engel J et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57(5):754–761PubMed
83.
Gervasoni JE Jr, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol 14(9):2443–2462PubMed
84.
Epstein JI et al (1986) Frozen section detection of lymph node metastases in prostatic carcinoma: accuracy in grossly uninvolved pelvic lymphadenectomy specimens. J Urol 136(6):1234–1237PubMed
85.
Campbell SC et al (1995) Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 46(3):352–355PubMed
86.
Yuh BE et al (2013) Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU Int 112(1):81–88PubMed
87.
Wilson TG et al (2015) Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 67(3):363–375PubMed
88.
Ecanow JS et al (2013) Axillary staging of breast cancer: what the radiologist should know. Radiographics 33(6):1589–1612PubMed
89.
Tokuda Y et al (2010) Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol 34(12):1862–1867PubMedPubMedCentral
90.
Howard JH et al (2017) Prognostic value of multiple draining lymph node basins in melanoma: a matched-pair analysis based on the John Wayne cancer institute experience. Front Oncol 7:172PubMedPubMedCentral
91.
Fukuda H et al (2000) Anatomic distribution of intraprostatic lymphatics: implications for the lymphatic spread of prostate cancer-a preliminary study. Prostate 44(4):322–327PubMed
92.
van der Poel HG et al (2017) Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU Int 120(2):204–211PubMed
93.
Holl G et al (2009) Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 36:1377–1382PubMed
94.
Weckermann D et al (2007) Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 51(6):1549–1556PubMed
95.
Miki J et al (2018) Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer. Prostate 78(6):419–425PubMed
96.
Hruby S et al (2015) Fluorescence guided targeted pelvic lymph node dissection for intermediate and high risk prostate cancer. J Urol 194(2):357–363PubMed
97.
Jeschke S et al (2012) Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging. Urology 80(5):1080–1086PubMed
98.
Wawroschek F et al (2003) The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43(2):132–136; discussion 137 PubMed
99.
Chennamsetty A et al (2017) Lymph node fluorescence during robot-assisted radical prostatectomy with indocyanine green: prospective dosing analysis. Clin Genitourin Cancer 15(4):e529–e534PubMed
100.
KleinJan GH et al (2014) Optimisation of fluorescence guidance during robot-assisted laparoscopic sentinel node biopsy for prostate cancer. Eur Urol 66(6):991–998PubMed
101.
Ramirez-Backhaus M et al (2016) Indocyanine green guided pelvic lymph node dissection: an efficient technique to classify the lymph node status of patients with prostate cancer who underwent radical prostatectomy. J Urol 196(5):1429–1435PubMed
102.
Yuh B et al (2012) Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer. Eur Urol 61(5):1004–1010PubMed
103.
Weckermann D et al (2007) Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 177(3):916–920PubMed
104.
Inoue S et al (2011) Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green. Can Urol Assoc J 5(4):254–259PubMedPubMedCentral
105.
Wawroschek F et al (2003) Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 70(4):303–310PubMed
106.
Reinhart MB et al (2016) Indocyanine green: historical context, current applications, and future considerations. Surg Innov 23(2):166–175PubMed
107.
Salem CE et al (2006) A preclinical study of prostate sentinel lymph node mapping with [99mTC]diethylenetetramine pentaacetic acid-mannosyl-dextran. J Urol 175(2):744–748PubMed
108.
Knapp DW et al (2007) Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol 52(6):1700–1708PubMedPubMedCentral
109.
Inoue S et al (2013) Identification of lymphatic pathway involved in the spread of bladder cancer: evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green. Can Urol Assoc J 7(5–6):E322–E328PubMedPubMedCentral
110.
van der Poel HG et al (2011) Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 60(4):826–833PubMed
111.
Manny TB, Patel M, Hemal AK (2014) Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients. Eur Urol 65(6):1162–1168PubMed
112.
van den Berg NS et al (2017) Multispectral fluorescence imaging during robot-assisted laparoscopic sentinel node biopsy: a first step towards a fluorescence-based anatomic roadmap. Eur Urol 72(1):110–117PubMed
113.
Lee HJ et al (2017) Fluorescence-based molecular imaging of porcine urinary bladder sentinel lymph nodes. J Nucl Med 58:547–553PubMed
114.
Maurer T et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 68(3):530–534PubMed
115.
116.
Veronesi U et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMed
117.
Weckermann D et al (2006) Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤ 10 ng/mL and biopsy Gleason score of ≤ 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 97(6):1173–1178PubMed
Metadata
Title
Sentinel node evaluation in prostate cancer
Authors
Ramkishen Narayanan
Timothy G. Wilson
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5-6/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-018-9936-4

Other articles of this Issue 5-6/2018

Clinical & Experimental Metastasis 5-6/2018 Go to the issue

Commentary

Future perspectives: cancer metastases

Research Paper

Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions

Review

Frontiers of cancer imaging and guided therapy using ultrasound, light, and microwaves

Research Paper

Detection of melanoma metastases with the sentinel node biopsy: the legacy of Donald L. Morton, MD (1934–2014)

Research Paper

Regional therapies for locoregionally advanced and unresectable melanoma

Research Paper

Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits